Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus

Back

ESC Premium Access

Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus

Session: Diabetes and heart disease

Topic: Metabolic Syndrome, Insulin, Insulin Resistance

Speaker: Doctor K. Katogiannis (Athens, GR)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Konstantinos Katogiannis

Attikon University Hospital, Athens (Greece)

1 presentation

0 follower

5 more presentations in this session

Regional distribution of diffuse fibrosis in the basal and mid-ventricular AHA segments in patients with type 2 diabetes

Speaker: Doctor A. Bojer (Gentofte, DK)

Circadian heart rate fluctuations predict 21-year cardiovascular and all-cause mortality in type 2 and type 1 diabetes

Speaker: Doctor L. Nesti (Pisa, IT)

The epicardial adipose tissue volume is in patients with type 2 diabetes mellitus associated with a lowered myocardial perfusion reserve

Speaker: Doctor A. Johansen (Herlev, DK)

Impact of diabetes on vascular endothelial growth factor D and cardiovascular mortality in patients with suspected or known coronary artery disease: the ANOX study

Speaker: Doctor H. Wada (Kyoto, JP)

Type 2 diabetes individuals have a shorter QRS duration, prolonged QTc interval, flatter T wave, and reduced left ventricular cycle volumes compared to matched controls in the UK Biobank

Speaker: Ms A. Bertrand (Oxford, GB)

Access the full session

Diabetes and heart disease

Speakers: Doctor K. Katogiannis, Doctor A. Bojer, Doctor L. Nesti, Doctor A. Johansen, Doctor H. Wada...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources